Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00125372
Status:
COMPLETED
Last Update Posted:
2019-01-08
First Post:
2005-07-29
Brief Title:
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Sponsor:
Dartmouth-Hitchcock Medical Center
Organization:
Dartmouth-Hitchcock Medical Center
Study Overview
Official Title:
A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn the effects on lung cancer of 2 new drugs Tarceva and Targretin given in combination before surgical removal of the tumor Tarceva is approved by the Food and Drug Administration FDA for lung cancer Targretin is approved for the treatment of cutaneous T-cell lymphoma This combination of drugs is experimental
Detailed Description:
Erlotinib 150mg and bexarotene 400mgm2 will be administered orally for 7-9 days prior to thoracotomy Plasma samples will be collected on the day before surgery and along with tissue samples on the day of the thoracotomy Analyses will be done on the resected specimen and it will be compared to the pre-study diagnostic specimen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None